Market need Diabetes management with a non-insulin approach targeting obese patients refractory to oral meds, presenting a clear alternative for clinicians seeking less burdensome therapies.

Global focus CE-marked and sold in Europe, Australia, and other markets, indicating readiness for international expansion and partnerships outside the USA.

Clinical validation Clinical trials showing DIAMOND therapy as effective as insulin with fewer side effects and reduced treatment burden, a strong differentiator for clinician education and payer conversations.

Small team agility Lean organization (2-10 employees) with $20M in funding and revenue in the low- to mid-range, suggesting opportunities for channel partnerships, OEM collaborations, and scalable manufacturing/fulfillment arrangements.

Technology edge Implantable pacemaker-like device delivering stomach-stimulating signals, offering a compelling narrative for neuromodulation and device-based diabetes management to engage surgeons, endocrinologists, and hospital systems.